Results 21 to 30 of about 94,936 (269)

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther, Galle, Peter R., Brenner, Baruch, Arnold, Dirk, Roessler, Hans-Peter, Thomaidis, Thomas, Schimanski, Carl Christoph, Schmidberger, Heinz, Rödel, Claus, Gockel, Ines, Möhler, Markus, Trarbach, Tanja, Lang, Hauke   +12 more
core   +1 more source

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients

Zhongliu Fangzhi Yanjiu, 2019
Objective To assess the efficacy of docetaxel rechallenge on castration-resistant prostate cancer (mCRPC) patients and to analyze prognostic factors. Methods We retrospectively reviewed the medical history of 120 mCRPC patients treated with the first ...
DUAN Liqun, ZHANG Qu, LIU Sanhe, DENG Kangli, WEI Shaozhong   +4 more
doaj   +1 more source

Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy

Cell & Bioscience, 2021
Background Mesenchymal stem cells (MSCs) have been proved to drive castration resistant prostate cancer (CRPC). In this study, we aim to investigate the contribution of MSCs to the development of docetaxel resistance in CRPC cells and its potential ...
Yang Yu, Fu-han Yang, Wen-tao Zhang, Ya-dong Guo, Lin Ye, Xu-dong Yao   +5 more
doaj   +1 more source

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer [PDF]

, 2006
A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic ...
Riemsma, R., Trowman, R., G Norman, E Fenwick, R Riemsma, Norman, G., Fenwick, E., Birtle, A., Collins, R., K Light, Light, K., A Birtle, Palmer, S., R Collins, S Palmer, R Trowman   +15 more
core   +1 more source

Docetaxel Toxicity Optimization in Esophageal Squamous Cell Carcinoma Cell Line YM-1: A Study of Cell Cycle and Doubling Time Effect

Medical Laboratory Journal, 2021
Background and objectives: Docetaxel is a chemotherapeutic agent commonly used for treatment of many cancers, including esophageal squamous cell carcinoma. Docetaxel induces G2/M phase cell cycle arrest and ultimately cell death.
Boshra haghi, Marie Saghaeian jazi, Mahdi zarie, Ayyoob Khosravi, mahboubeh tajaldini, Jahanbakhsh Asadi   +5 more
doaj  

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy

BMC Cancer, 2007
Background Previous pharmacokinetic studies with docetaxel have mostly used 3-weekly (75 mg/m2 and 100 mg/m2) or weekly regimens (35–40 mg/m2). The pharmacokinetics and radiosensitizing efficacy of weekly 20 mg/m2 docetaxel, has however not been well ...
Kristensen Vessela, Aamdal Steinar, Andersen Anders, Fr Brunsvig Paal, Olsen Harald   +4 more
doaj   +1 more source

Formation of Docetaxel-related Substances in the Polymer Particles During Storage and Gamma-treatment

Разработка и регистрация лекарственных средств, 2020
Introduction. Docetaxel is widely used for cancer treatment. Actual issue for newly developed polymer-based Docetaxel formulations is applicability of current quality requirements.
Yu. I. Poltavets, S. V. Aleshin, V. V. Zavarzina, A. I. Murav’eva, A. A. Soboleva, I. A. Tubasheva, S. L. Kuznetsov   +6 more
doaj   +1 more source

Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC) [PDF]

, 2009
Background NSCLC exhibits considerable heterogeneity in its sensitivity to chemotherapy and similar heterogeneity is noted in vitro in a variety of model systems.
Gyi, Mya, Francis G Gabriel, Sharon Glaysher, Polak, ME, Amer, K, Smith, Mark E., Cree, IA, Bruce Addis, Poole, Matthew, Andreotti, Peter Eugene, Joe Rahamim, Goldthorpe, Zoe, Peregrin, K, Rahamim, Joe, Johnson, Penny, Marta E Polak, Mya Gyi, Poole, M, Glaysher, S, Yiannakis, Dennis, Ian A Cree, Gabriel, Francis G., Johnson, P, Zoe Goldthorpe, Dennis Yiannakis, Amer, Khalil, Addis, Bruce, Amer, Khalid, Peter E Andreotti, Addis, B, Gulliford, Tim J., Modi, Paul, Rahamim, J, Andreotti, PE, Andreotti, Peter E., Polak, Marta E., Gulliford, Tim J, Khalid Amer, Knight, LA, Narayanan, A, Smith, ME, Glaysher, Sharon, Penny Johnson, Peregrin, Katharine, Louise A Knight, Paul Modi, Tim J Gulliford, Goldthorpe, Z, Gyi, M, Addis, B. J., Ajit Narayanan, Mark E Smith, Narayanan, Ajit, Katharine Peregrin, Modi, P, Matthew Poole, Gabriel, FG, Yiannakis, D, Gulliford, TJ, Knight, Louise A., Cree, Ian A.   +60 more
core   +2 more sources

Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel’s activity by suppressing the NF-kB signaling pathway

Frontiers in Oncology, 2022
Ubiquitin-specific protease 8 (USP8) has been recently reported to be involved in tumorigenesis. Prostate cancer (PCa) is the most diagnosed malignancy among men, but USP8’s role in PCa is not yet investigated comprehensively.
Md. Tariqul Islam, Fang-Zhi Chen, Han-Chun Chen, Abdul Wahid   +3 more
doaj   +1 more source

Study of the radiosensitization of docetaxel in human esophageal squamous carcinoma ECA109 cell line

Pakistan Journal of Pharmaceutical Sciences, 2021
The aim of this study was to determine the radio sensitization of docetaxel in human esophageal squamous carcinoma ECA109 cell line by observing the effects of docetaxel in ECA109 cell proliferation, cell cycle distribution, apoptosis rate and related ...
Li He, Liang Dong, Sujing Zhang, Yongqian Zhang, Zheng Zheng, Ying Guo, Liping Guo, Changwen Bo   +7 more
doaj   +1 more source